胰腺癌 - 图文

2014ASCO胰腺癌摘要翻译

1、 Prognostic factors of response to adjuvant chemotherapy after curative resection for pancreatic

ductal adenocarcinoma: Prognostic impact of CDA, predictive value of DPD for 5FU efficiency, and hENT1 for gemcitabine.

Subcategory: Pancreatic Cancer

Category:

Gastrointestinal (Noncolorectal) Cancer

Meeting:

2014 ASCO Annual Meeting Session Type and Session Title:

This abstract will not be presented at the 2014 ASCO Annual Meeting but has been published in conjunction with the meeting. Abstract Number:

e15191

Citation:

J Clin Oncol 32, 2014 (suppl; abstr e15191)

Author(s):

Xavier Edouard Truchet, Claire Mallaret, Véronique Secq, Julien Mancini, Yves patrice le Treut, Vincent Moutardier, Mehdi Oua?ssi, Marion Rubis, Emilie Nouguered, Jean Delgrande, marie-No?lle Lavaut, Joseph Ciccolini, Mohamed Gasmi, Stéphane Garcia, Jean Francois Seitz, Laetitia Dahan; CHU Timone, Marseille, France; H?pital Nord service d'Anatomie et

Cytologie Pathologiques, Marseille, France; University Hospital La Timone, Marseille, France; CHU Conception, Marseille, France; CHU NORD, Marseille, France; CRO2, Marseille, France; Transfert Oncology Laboratory, Nord University Hospital of Marseille, Marseille, France; H?pital Nord APHM, Marseille, France; La Timone University Hospital, Marseille, France; La Timone, Marseille University Hospital, Marseille, France

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^). Abstract Disclosures 2014 ASCO Annual Meeting Proceedings Errata Abstract:

Background: Since 2005, adjuvant chemotherapy with gemcitabine (Gem) or 5fluorouracil (5FU) plus folinic acid for 6 months is a standard in resected pancreatic cancer. Predictive factors of efficiency of these 2 schemes seems necessary to offer patients a treatment card. This retrospective study evaluated the prognostic value of 7 histological markers (DPD, TS, CDA, hENT1, hCNT3, S100A2, and SMAD 4), and their impact on the efficacy chemotherapy with Gem or 5FU. Methods: From 230 pancreatic resections for cancer, we retrospectively included 193 patients with pancreatic surgery for pancreatic

adenocarcinoma (PAC) between March 2005 and December 2012 in three hospitals in Marseille. A TMA (Tissue Micro Array) was constructed using tissue core samples from these tumors. Of these, 63 patients were excluded from the analysis: 9 early postoperative deaths, 7 metastatic disease or R2 resection, 6 received neo-adjuvant treatment, 14 lost of follow up, 27 not included in the TMA. Finally, 123 patients were available: 108 received postoperative chemotherapy (69 GEM, 32 LV5FU2, 7 others), 13 didn't receive adjuvant treatment and 2 was unknown. 7 immunohistochemical markers were performed on the TMA: SMAD 4, TS, hCNT3, DPD, CDA, hENT1,

S100A2. Results: OS was increased in patients with no CDA tumoral expression versus low or high (38.6 months vs 20.7 months p = 0.03). This difference remained significant in multivariate analysis (p = 0.02). Intratumoral overexpression of DPD is a pejorative predictive factor of OS and RFS in patients treated with 5FU: Respectively 25.7 months for none or low expression vs 10.4 months for high expression (p = 0.04), and 12.3 months vs 4.9 months, (p = 0.04). Intratumoral high expression of hENT1 is a predictive factor of better RFS in patients receiving Gem (14.9 months vs 11.5 months, p= 0.045). Conclusions: Loss of expression of intratumoral CDA is prognostic of better

survival in patients undergoing curative PAC. The low expression of DPD is predictive of better OS and RFS in patients treated with 5FU. High expression of hENT1 is predictive of better RFS in patients treated with Gem

影响胰腺导管腺癌术后辅助化疗的预后因素：CDA对预后影响，5-Fu联合DPD及吉西他滨联合hENT1 预后价值。

摘要：背景：从2005年开始，吉西他滨或者5-Fu联合叶酸治疗6个月是胰腺癌术后的标准治疗方案。这个回顾性研究是评估7个组织学标记的预后价值(DPD, TS, CDA, hENT1, hCNT3, S100A2及 SMAD 4)以及了解它们对吉西他滨或5-Fu化疗有效性的影响。方法：从230名胰腺癌术后患者中，我们回顾了马赛市三个医院从2005年3月至2012年12月193名经过胰腺癌手术的胰腺腺癌患者。 63 名患者因为9名提前死亡, 7 名远处转移或 R2 切除, 6 名接受新辅助治疗, 14名失访, 27名没有行免疫检测而均未入组.。123 名患者参加研究：108 名患者接受术后化疗 (69 GEM, 32 LV5FU2, 7 其他)，13 名没有接受化疗， 2名未知。7 个组织指标进行免疫检测，包括SMAD 4, TS, hCNT3, DPD, CDA, hENT1, S100A2。结果：与CDA或高或低表达相比，CDA表达阴性患者OS延长（30.6个月vs20.7个月，P=0.03)。瘤内DPD的过表达对5-Fu化疗患者的OS及RFS是不好的预后因素：相应地表达阴性或低表达患者 25.7 个月vs 高表达患者10.4 个月 (p = 0.04), 12.3 个月vs 4.9个月(p = 0.04).。瘤内hENT1高表达是影响Gem治疗患者RFS较好的预后因素 (14.9 个月 vs 11.5 个月, p= 0.045)。结论： 瘤内CDA表达阴性是影响胰腺癌术后较好的预后因素。DPD的低表达是接受5-Fu患者延长OS及RFS较好的预后因素。 hENT1的高表达是延长接受Gem治疗患者RFS较好的预后因素。

2、Prognostic value of serum carbohydrate 19-9 in patients receiving gemcitabine-based neoadjuvant therapy for pancreatic cancer. Subcategory: Pancreatic Cancer Category:

Gastrointestinal (Noncolorectal) Cancer Meeting:

2014 ASCO Annual Meeting

Session Type and Session Title:

This abstract will not be presented at the 2014 ASCO Annual Meeting but has been published in conjunction with the meeting. Abstract Number:

e15189

Citation:

J Clin Oncol 32, 2014 (suppl; abstr e15189)

Author(s):

Kabir Mody, Joseph J. Shatzel, Spencer L. James, Rebecca Wang, Thomas Anthony Colacchio, Richard J. Barth, Bassem I. Zaki, Michael J. Tsapakos, Arief A. Suriawinata, John E. Sutton, Stuart R. Gordon, Timothy B. Gardner, Kerrington D. Smith, Gregory H. Ripple, Kathryn Cunningham Hourdequin, Gregory J. Tsongalis, Elizabeth Boutin McGrath, J. Marc Pipas; Dartmouth

Hitchcock Medical Center, Lebanon, NH; Dartmouth-Hitchcock Medical Center, Lebanon, NH; White River Junction VA Medical Center, White River Junction, VT

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^). Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

2014 ASCO Annual Meeting Proceedings Errata

Abstract:

Background: The role of neoadjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) remains unclear, but has demonstrated benefit in many studies. CA 19-9 is a commonly used tumor marker in the clinical management of PDAC, but its prognostic role in neoadjuvant therapy is not well defined. The goal of this study was to determine the relationship between CA 19-9 changes after neoadjuvant therapy and subsequent outcomes in patients with non-metastatic PDAC. Methods: We performed a retrospective review of all patients with resectable, borderline resectable, and locally advanced PDAC

who received neoadjuvant therapy at our institution between 1996 and 2012. For inclusion, patients needed a serum CA 19-9 >40 U/ml and bilirubin ≤2 mg/dl at the initiation of

therapy. We evaluated associations between Ca 19-9 pre- and post- neoadjuvant therapy (NT) and outcome variables including completion of surgery, overall survival, and progression-free survival. Results: Of the 145 patients included, 30 had resectable

disease (20%), 56 had borderline resectable disease (39%), and 59 had locally advanced disease (41%). Post-NT CA 19-9 normalized to <40U/ml in 54 patients (37%). Seventy patients (48%) underwent resection. Patients with post-NT CA 19-9 <40U/ml had significantly higher odds of undergoing resection (OR 2.95 p = 0.02). Normalization of post-NT CA19-9 was associated with improved survival (HR=0.58 p=0.006), even after adjusting for successful resection. CA19-9 normalization was predictive of longer OS in patients with borderline disease (HR (0.320, p = 0.001). Completion of resection was also prognostic for overall survival (HR 0.30 p<0.001). Median OS in resected patients who normalized CA 19-9 was 27.3 months, and 20.9 months in those who did not (p = 0.10). Normalization of post-NT CA19-9 in those who did not complete resection was also

associated with longer overall survival, with a median OS of 15.1 months, compared to 8.5 months (p=0.032). Conclusions: Normalization of CA 19-9 to <40U/ml with neoadjuvant therapy is highly prognostic for resection and overall survival in patients receiving gemcitabine-based neoadjuvant chemoradiation therapy.

血清CA199对接受吉西他滨为基础的新辅助化疗胰腺癌患者的预后价值

背景：新辅助化疗对胰腺导管腺癌（PDAC）的影响尚不明确。CA199作为PDAC临床常用的检测指标，其对新辅助化疗的预后作用也不明确。这个研究的目的是了解接受新辅助治疗后CA199的改变对没发生转移的PDAC预后的影响。方法：我们回顾性的研究了所有从1996至2012年接受新辅助治疗的可切除、边缘可切除及局部进展的PDAC患者。开始治疗前，CA199>40 U/ml及胆红素≤2 mg/dl 。我们评估了化疗前后CA199的变化及预后价值，包括对手术、OS及PFS的影响。

结果：入组145名患者，其中30名可切除(20%)，56名边缘可切除 (39%)，59名局部进展(41%)。化疗后54名(37%)患者CA199<40U/ml 。70名(48%)患者进行手术。化疗后 CA 19-9 <40U/ml 患者手术率较高 (OR 2.95 p = 0.02)。化疗后CA199正常可以提升生存时间(HR=0.58 p=0.006)。CA199正常可以延长边缘可切除患者OS (HR (0.320, p = 0.001)。手术切除也是延长OS的预后因素(HR 0.30 p<0.001)。CA199降至正常与CA199未降至正常术后患者中位OS：27.3 个月及20.9个月 (p = 0.10)。没有接受手术治疗患者化疗后CA199正常患者也有更长生存期，即中位OS15.1 个月及 8.5个月。结论：接受以吉西他滨为基础的新辅助化疗后CA 19-9 t降至<40U/ml正常是手术切除及OS较好的预后因素。 3. Second-line treatment in patients with FOLFIRINOX-refractory pancreatic adenocarcinoma (PDAC): Doublets or single-agent chemotherapy? Subcategory: Pancreatic Cancer Category:

Gastrointestinal (Noncolorectal) Cancer Meeting:

2014 ASCO Annual Meeting

Session Type and Session Title:

This abstract will not be presented at the 2014 ASCO Annual Meeting but has been published in conjunction with the meeting. Abstract Number:

e15186

Citation:

J Clin Oncol 32, 2014 (suppl; abstr e15186)

Author(s):

Chiara Pellei, Andrea Lanese, Alessandro Bittoni, Kalliopi Andrikou, Matteo Santoni, Alessandro Conti, Giuseppe Tonini, Marco Russano, Daniele Santini, Stefano Cascinu; Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - GM Lancisi - G Salesi, Ancona, Italy., ancona, Italy; Clinica di Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy; Scuola di Specializzazione in

Oncologia Medica UNIVPM, Ancona, Italy; Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy; Scuola di

Specializzazione in Urologia, Università Politecnica delle Merche, Ancona, Italy; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy; Department of Medical Oncology Campus Bio-Medico University, Rome, Italy; Clinica di Oncologia Medica, A.O. Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^). Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

2014 ASCO Annual Meeting Proceedings Errata

Abstract:

Background: FOLFIRINOX represents an active regimen in first-line treatment of advanced pancreatic cancer (APC) patients (pts) with good performance status (PS). Currently, there are no accepted standard regimens in second-line therapy for patients with disease progression and data about efficacy of chemotherapy after FOLFIRINOX failure are lacking . Methods: We retrospectively investigated clinical and laboratory

characteristics (including blood count, LDH and CA19.9) of APC pts treated between June 2011 and October 2013 in two italian institutions (AOU Ospedali Riuniti-Ancona and

Campus Biomedico-Roma) with either doublet or single agent as second-line therapy after FOLFIRINOX failure. Survival estimates were quantified using Kaplan Meier curves, and differences between groups were compared with the log-rank test. Results: Among 48 pts

treated with FOLFIRINOX as first-line chemotherapy, 29 pts received second-line treatment (60.4%). PDAC was locally advanced in 12 (41%) and metastatic in 17 pts (59%). Median age at diagnosis was 58.8 years (range 37-72); 19 pts were males; 13 females. Patients who received second line single agent (gemcitabine, docetaxel or nab-paclitaxel) or doublets (gemcitabine with either capecitabine, cisplatin or docetaxel) were 13 and 16, respectively. According to RECIST criteria, 2 pts achieved PR 2 (6.9%); 9 (31%) SD for ≥9 wks; 18 (62.1%) PD; Median progression-free survival (PFS) was 2.7 months and median overall survival (OS) was 3.41 months. ECOG≤ 1 resulted a favorable prognostic factor (p<0.05). Patients treated with single-agent chemotherapy had a better outcome in terms of OS (p=0.048) as compared with doublets, while no significant differences were found in terms of PFS and overall response rate. Conclusions:Our findings suggest that the choice of second line therapy in patients with

FOLFIRINOX-refractory PDACs should be carefully evaluated. Single agent

chemotherapy may represent a better option compared to combinations, although these data should be confirmed in prospective trials.

FOLFIRINOX耐药的胰腺腺癌（PDAC）患者的二线治疗

方法：我们回顾性调查了从2011年6月至2013年10月在意大利的两个研究所的胰腺癌患者的临床及实验室特征。均FOLFIRINOX治疗失败后改用减少药物或用单药二线治疗。结果：48名接受 FOLFIRINOX一线治疗患者，29(60.4%)名患者接受二线治疗，12 (41%) 名患者局部进展，17 (59%)名患者远处转移。接受二线单药治疗（吉西他滨、多西紫杉醇或紫杉醇）或药物减量（吉西他滨联合卡培他滨或顺铂或多西紫杉醇）人数分别为13及16位。根据RECIST 评判标准，2 名患者PR 2(6.9%); 9 (31%) SD 9周以上; 18 (62.1%) PD; 中位PFS2.7 个月，中位 (OS) 3.41 个月。 ECOG≤ 1是较好预后因素(p<0.05)。与药物减量相比，接受单药化疗患者获得较长OS(p=0.048) ，而PFS及ORR没有统计学意义。 结论：FOLFIRINOX治疗失败的PDAC患者二线的选择需要认真评估。与联合相比，单药化疗可能是更佳的选择，但是这些数据还需要前瞻性实验证实。

4、Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy. Subcategory: Pancreatic Cancer Category:

Gastrointestinal (Noncolorectal) Cancer Meeting:

2014 ASCO Annual Meeting

Session Type and Session Title:

General Poster Session, Gastrointestinal (Noncolorectal) Cancer Abstract Number:

4132

Citation:

J Clin Oncol 32:5s, 2014 (suppl; abstr 4132)

Author(s):

Thomas H. Cartwright, Aimee Ginsburg, Lalan S. Wilfong, Robyn K. Harrell, J. Russell Hoverman; Ocala Oncology, Ocala, FL; The US Oncology

Network/McKesson Specialty Health, The Woodlands, TX; Texas Oncology Presbyterian, Dallas, TX; Texas Oncology, The Woodlands, TX

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^). Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

2014 ASCO Annual Meeting Proceedings Errata

Abstract:

Background: Pancreatic cancer (PC) is the fourth leading cause of death in the United States. It is estimated that 46,420 patients will be diagnosed in 2014 and 35,590 will die (Siegel, CA Cancer J Clin 2014). Gemcitabine has long been the standard of care chemotherapy. Recent advances in treatment created the combination regimens (oxaliplatin, irinotecan, leucovorin, fluorouracil [FOLFIRINOX]) and gemcitabine, nab-paclitaxel (GN) for patients with good Karnofsky performance status (PS) (Conroy, NEJM 2011; Von Hoff, NEJM 2013). This retrospective analysis was conducted as an update to results reported at ASCO 2013 (Cartwright, JCO 2013) to evaluate characteristics and overall survival (OS) of patients receiving FOLFIRINOX and

gemcitabine-based treatments in a large outpatient community setting. This is the largest study describing FOLFIRINOX patients to date. Methods: Patients with advanced PC treated at practices in The US Oncology Network entered into the iKnowMed (iKM)

database between June 2010 and November 2013 were included. Patterns of treatment were characterized by the median age at diagnosis, sex, PS, and first-line metastatic chemotherapy prescribed. The primary endpoints of the analysis were OS and uptake of FOLFIRINOX within The Network. Results: Compared to ASCO 2013 results, 700

additional patients were identified. Of the 2,422 total patients, 27% received FOLFIRINOX (24% in 2013) and 73% received gemcitabine-based therapy (76% in 2013). Increased utilization of FOLFIRINOX for good PS patients began in June 2010 and GN April 2013. For all patients (55% male), the median age at diagnosis was 67 and 95% had a PS of 70% or greater. When controlled for age and PS, the OS was significantly longer for

FOLFIRINOX (11.2 mos) versus gemcitabine (7.2 mos) (p<0.0001). Median OS for GN (n=189) was 10.2 mos, despite shorter follow up time. Conclusions: Utilization of

FOLFIRINOX and GN has continued to increase after the publication of phase III trials. Our data in a community setting continues to support a survival advantage for

FOLFIRINOX as well as GN. The magnitude of benefit appears slightly better in the

community; therefore, we agree that FOLFIRINOX should become a standard of care for good PS patients.

进展期胰腺癌患者的一线化疗：FOLFIRINOX VS以吉西他滨为基础的化疗

方法：从2010年6月至2013年12月美国肿瘤中心的进展期胰腺癌（PC）患者收集入数据库。主要观察终点包括OS。结果：与ASCO 2013 结果相比，700 名额外患者加入。入组的所有2422名患者，27%接受FOLFIRINOX 治疗（2013年是24%），73%接受以吉西他滨为基础的化疗（2013年是76%）。增加的使用FOLFIRINOX及PS较好患者在2010年6月，而紫杉醇（GN）组在2013年4月。所有患者（55%男性），中位诊断年龄67，95%PS>70。当按年龄及PS入组， FOLFIRINOX 的OS要长于吉西他滨（11.2个月vs7.2个月，p<0.0001）。GN (n=189) OS为10.2 个月。结论：FOLFIRINOX及 GN的利用在3期实验工部分后增多。我们的数据进一步证实了FOLFIRINOX 及GN的好处。在获得利益方面似乎较好，我们同意FOLFIRINOX应该成为一个PS较好患者的标准。

5、A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. Subcategory: Pancreatic Cancer Category:

Gastrointestinal (Noncolorectal) Cancer Meeting:

2014 ASCO Annual Meeting

Session Type and Session Title:

General Poster Session, Gastrointestinal (Noncolorectal) Cancer Abstract Number:

TPS4161

Citation:

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4161)

Author(s):

Susan M. Domchek, Robert R. McWilliams, Andrew Eugene Hendifar, Rachna T. Shroff, Lawrence P. Leichman, Ron Epelbaum, Ravit Geva, George P. Kim, Steven R. Alberts, Robert A. Wolff, Andrew R. Allen, Heidi Giordano, Mitch Raponi, Jeffrey D. Isaacson, Lindsey Rolfe, Andrew Biankin, Robert H. Vonderheide; University of Pennsylvania, Philadelphia, PA; Mayo Clinic, Rochester, MN; Cedars-Sinai Medical Center, Los Angeles, CA; The

University of Texas MD Anderson Cancer Center, Houston, TX; New York University School of Medicine, New York, NY; Rambam Health Care Campus, Haifa, Israel; Sourasky Medical Center, Tel Aviv, Israel; Mayo Clinic,

Jacksonville, FL; Clovis Oncology, Inc., San Francisco, CA; Clovis Oncology, Inc., Boulder, CO; Clovis Oncology, Inc., Cambridge, United Kingdom; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; The University of Pennsylvania, Philadelphia, PA

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

2014 ASCO Annual Meeting Proceedings Errata

Abstract:

Background: Approximately 5% of unselected pancreatic cancer (PC) patients (pts), 10% of PC pts of Ashkenazi Jewish descent, and up to 19% of familial PC families, harbor a germline BRCA mutation. PARP inhibitors (PARPi) have exhibited clinical activity in pts with a BRCA mutation. Rucaparib, an oral PARPi, is being developed for treatment of cancers associated with homologous recombination repair (HRR) deficiency due to a BRCA mutation or other HRR pathway defect. Rucaparib has demonstrated clinical activity (RECIST and CA-125 responses) in pts with BRCAmut pancreatic, ovarian, or

breast cancer in an ongoing Phase 1/2 study (NCT01482715). Clinical activity of PARPi in BRCAmut PC combined with the paucity of active 2nd-line therapies support evaluation of rucaparib in PC pts with a deleterious BRCA mutation. Methods: Study CO-338-023

(NCT02042378) is a single-arm, open-label Phase 2 trial of continuous rucaparib in up to 100 pts with pancreatic ductal adenocarcinoma (or related subtype) and a known

deleterious BRCA mutation (germline or somatic). Pts must have received at least 1, but no more than 2, prior regimens for locally advanced or metastatic disease and have relapsed disease, or are no longer able to tolerate chemotherapy due to toxicity and radiologic assessment confirms no response to such treatment. Other key inclusion criteria include measurable disease, ECOG PS 0 or 1, and adequate organ function. Pts with endocrine tumors or prior PARPi treatment are excluded. Pts will take rucaparib continuously and be evaluated for safety every 2–4 wks, disease status (CT scans,

CA19–9) every 4–8 wks until disease progression, and then survival every 4 wks. Blood and archival tumor tissue (if available) will be collected from all pts. The primary endpoint is ORR by RECIST v1.1. Key secondary endpoints include duration of response, PFS, OS, and safety. Exploratory analyses include gene sequence and structural rearrangements of tumor DNA, and evaluation of circulating tumor DNA. A group sequential interim

monitoring plan will be implemented to stop the study early for either superior efficacy or futility. Interim analyses will occur after every 10th pt enrolled has sufficient disease assessment data available. Clinical trial information: NCT02042378. BRCA突变胰腺癌患者服用rucaparib的2期，开放性研究（正在进行） Rucaparib，一种口服的 PARP抑制剂，已经被用于治疗由于BRCA突变或其他同源复合修复（HRR）通路缺失所引起的HRR相关肿瘤。

方法：Study CO-338-023 (NCT02042378) 是一个单臂，开放的2期临床研究。继续将rucaparib 用于100名胰腺导管腺癌或相关亚型患者，已确定 BRCA 突变。患者必须接受至少1种,但不超过2种之前的方案，已局部晚期或发生转移性，或由于毒性不能耐受化疗和放射评估，或者没有回应这样的治疗。其他关键入选标准包括可衡量的疾病,ECOG PS 0或1,和尚可的器官功能。患者患有其他内分泌肿瘤或之前PARPi治疗被排除在外。rucaparib连续服用，每2 - 4周评估安全性、疾病状态(CT,CA19-9)每4 - 8周评估直到疾病进展,然后每4周评估生存。收集所有患者血液和肿瘤组织(如果有的话)。主要目标是ORR。次要终

点包括反应持续的时间、PFS,、OS及安全性。探索性分析包括肿瘤DNA的基因序列和结构重组,和循环肿瘤DNA的评估。 6、C-kit mRNA expression in pancreatic adenocarcinoma and matched stromal tissue: Prognostic and therapeutic implications. Subcategory: Pancreatic Cancer Category:

Gastrointestinal (Noncolorectal) Cancer Meeting:

2014 ASCO Annual Meeting

Session Type and Session Title:

This abstract will not be presented at the 2014 ASCO Annual Meeting but has been published in conjunction with the meeting. Abstract Number:

e15185

Citation:

J Clin Oncol 32, 2014 (suppl; abstr e15185)

Author(s):

Peter Philipp Grimminger, Craig Stephens, Dirk Waldschmidt, Stephanie H. Astrow, Hans-Michael Steffen, Jack Hsiang, Gary Zeger, Arnulf H H?lscher, Martin K. H. Maus; Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany; Response Genetics, Inc., Los Angeles, CA; Department of Gastroenterology and Hepatology, University of Cologne, Cologne, Germany; Pathway Diagnostics, Los Angeles, CA; University of Cologne, Department of Gastroenterology and Hepatology, Cologne, Germany; Keck School of Medicine, Department of Pathology, University of Southern California, Los Angeles, CA; Department of General, Visceral, and Tumor Surgery, University of Cologne, Cologne, Germany

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^). Abstract Disclosures

2014 ASCO Annual Meeting Proceedings Errata

Abstract:

Background: Pancreatic adenocarcinoma is one of the most aggressive malignancies with poor overall survival rates. C-Kit is a transmembrane receptor tyrosine kinase known to affect various characteristics of certain in various solid cancers. This study investigated the prognostic significance of tumorous c-Kit mRNA expression in pancreatic

carcinoma. Methods: FFPE tumor specimens from 58 patients with resectable pancreatic

本文来源：https://www.bwwdw.com/article/2zsp.html